Caveolin-1 and-2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease

被引:34
|
作者
van Helmond, Z. K. [1 ]
Miners, J. S. [1 ]
Bednall, E. [1 ]
Chalmers, K. A. [1 ]
Zhang, Y. [1 ]
Wilcock, G. K. [1 ]
Love, S. [1 ]
Kehoe, P. G. [1 ]
机构
[1] Univ Bristol, Dementia Res Grp, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England
关键词
Alzheimer's disease; amyloid beta peptide; caveolin-1; caveolin-2; cerebral amyloid angiopathy; tunica media;
D O I
10.1111/j.1365-2990.2006.00815.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebral amyloid angiopathy (CAA) affects over 90% of patients with Alzheimer's disease (AD) and increases the risk of cerebral haemorrhage and infarction. Caveolae - cholesterol-enriched plasmalemmal microinvaginations - are implicated in the production of amyloid beta peptide (A beta). Caveolin-1 (CAV-1) is essential for the formation of caveolae. Caveolin-2 (CAV-2) is expressed at the plasma membrane only when in a stable hetero-oligomeric complex with CAV-1. CAV-1 and CAV-2 are highly co-expressed by endothelium and smooth muscle. Recent studies suggest that down-regulation of CAV-1 causes a reduction in alpha-secretase activity and consequent accumulation of A beta. We have used quantitative immunohistochemical techniques to assess the relationship between CAV-1 and CAV-2 with respect to A beta accumulation in the cerebral vasculature in a series of post mortem brains. CAV-1 and CAV-2 were co-expressed within the tunica media and endothelium of cerebral blood vessels. There were regional differences in CAV-1 immunolabelling, which was significantly greater in the frontal cortex and white matter than in the parietal lobe (in both control and AD cases) or the temporal lobe (in AD alone). However, CAV-1 labelling in AD did not differ from that in controls in any of the three lobes examined. Assessment of CAV-1 labelling in relation to the severity of CAA showed CAV-1 to be significantly increased in the frontal white matter in a subgroup of AD cases with absent/mild CAA compared with controls with absent/mild CAA and to AD cases with moderate/severe CAA, but the latter groups did not show significant differences from one another. CAV-1 labelling did not vary with age, gender, APOE genotype, post mortem delay or brain weight. Only segments of blood vessels with particularly abundant A beta and extensive loss of smooth muscle actin showed loss of CAV-1 and CAV-2 from the tunica media. Within these vessels endothelial CAV-1 was preserved and discontinuous CAV-2 labelling was noted along the outer aspect of the vessel wall. Our findings suggest that alterations in the expression of vascular CAV-1 and CAV-2 are unlikely to play a role in the development of CAA in AD.
引用
收藏
页码:317 / 327
页数:11
相关论文
共 50 条
  • [31] A Shift in Microglial β-Amyloid Binding in Alzheimer's Disease Is Associated with Cerebral Amyloid Angiopathy
    Zabel, Matthew
    Schrag, Matthew
    Crofton, Andy
    Tung, Spencer
    Beaufond, Pierre
    Van Ornam, Jon
    Coppola, Giovanni
    Vinters, Harry
    Kirsch, Wolff
    NEUROLOGY, 2013, 80
  • [32] A Shift in Microglial -Amyloid Binding in Alzheimer's Disease Is Associated with Cerebral Amyloid Angiopathy
    Zabel, Matthew
    Schrag, Matthew
    Crofton, Andrew
    Tung, Spencer
    Beaufond, Pierre
    Van Ornam, Jon
    DiNinni, Angie
    Vinters, Harry V.
    Coppola, Giovanni
    Kirsch, Wolff M.
    BRAIN PATHOLOGY, 2013, 23 (04) : 390 - 401
  • [33] Oligomeric Aβ in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, APOE Genotype and Cerebral Amyloid Angiopathy
    van Helmond, Zoe
    Miners, James S.
    Kehoe, Patrick G.
    Love, Seth
    BRAIN PATHOLOGY, 2010, 20 (02) : 468 - 480
  • [34] Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
    Roy O Weller
    Stephen D Preston
    Malavika Subash
    Roxana O Carare
    Alzheimer's Research & Therapy, 1
  • [35] Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
    Weller, Roy O.
    Preston, Stephen D.
    Subash, Malavika
    Carare, Roxana O.
    ALZHEIMERS RESEARCH & THERAPY, 2009, 1 (02):
  • [37] Increased caveolin-1 expression in Alzheimer's disease brain
    Gaudreault, SB
    Dea, D
    Poirier, J
    NEUROBIOLOGY OF AGING, 2004, 25 (06) : 753 - 759
  • [38] Neurotoxicity and physicochemical properties of Aβ mutant peptides from cerebral amyloid angiopathy -: Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease
    Murakami, K
    Irie, K
    Morimoto, A
    Ohigashi, H
    Shindo, M
    Nagao, M
    Shimizu, T
    Shirasawa, T
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) : 46179 - 46187
  • [39] Alzheimer’s Silent Partner: Cerebral Amyloid Angiopathy
    Tanya L. Cupino
    Matthew K. Zabel
    Translational Stroke Research, 2014, 5 : 330 - 337
  • [40] Histochemical character of amyloid plaques and cerebral amyloid angiopathy in Alzheimer disease
    Apathy, A.
    Bely, M.
    Majtenyi, K.
    Sebestyen, T.
    Szabo, Szentjobi T.
    VIRCHOWS ARCHIV, 2009, 455 : 316 - 316